Program
AG-181
A development code.
Its studies are mostly in Phenylketonurias, led by Agios Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agios Pharmaceuticals | 21 open or running | phase 1since Feb 23, 2024 | Feb 23, 2024 | Jan 17, 2028phase 1 · NCT07241234 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 23, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06286033 · 88 enrolled · United States
- Nov 17, 2025Phase 1 study in PhenylketonuriasNCT07241234 · 20 planned · United States, Poland
Ahead
- Jan 17, 2028Primary completion: phase 1 study in PhenylketonuriasNCT07241234
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07241234Phenylketonurias · United States, Poland | 1 | Recruiting | Jan 17, 2028 | 20 |
| NCT06286033Healthy Volunteers · United States | 1 | Completed | Oct 9, 2025 | 88 |
How it is read
Names in the registry
- “AG-181”, 2 entries
Codes read as this program: AG181.
Conditions, from the studies’ own filings
- Phenylketonurias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.